Visen Pharmaceutical HK$783.3 million IPO
The shares are listed on the HKEX
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
MIXUE HK$3.45 billion IPO
We advised MIXUE on its IPO and HKEX listing
Live Oak Acquisition V $230 million IPO
The units are listed on the Nasdaq Global Market
Rithm Acquisition $230 million SPAC IPO
We advised Rithm Acquisition Corp., a SPAC, on its IPO and NYSE listing
BioVersys CHF 80 million IPO and concurrent private placement
We advised AMR Action Fund on its investment in BioVersys
SailPoint $1.4 billion IPO
The shares are listed on the Nasdaq Global Select Market
Maze Therapeutics $140 million IPO
The shares are listed on Nasdaq
Kioxia Holdings ¥120.4 billion IPO
The shares are listed on the Tokyo Stock Exchange
Venture Global $1.75 billion IPO
We advised Venture Global on its IPO and NYSE listing
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing